
|Videos|April 28, 2022
Tarsus pipeline advances program for Demodex blepharitis
Author(s)Kassi Filkins
Last year, the company announced the data from the Saturn-1 study for TP-03, the first potential product to treat Demodex blepharitis, and the product is now in the phase 3 trial (Saturn-2). Aziz Mottiwala, chief commercial officer for Tarsus, gives a company update on the pipeline for their program for Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
3
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
4
Optigo Biotherapeutics names Andreas Wallnöfer, PhD, MBA, to board as lead retinal program advances
5


















































.png)


